IPP Bureau
Kindeva appoints David Stevens as new CEO
By IPP Bureau - January 20, 2026
Stevens succeeds Milton Boyer, who has stepped down as CEO but will remain closely involved with the business as an independent member of Kindeva’s Board of Directors
Alto Neuroscience bags new US patent for depression drug ALTO-207
By IPP Bureau - January 20, 2026
ALTO-207 combines pramipexole, a dopamine D3-preferring D3/D2 agonist approved for Parkinson’s disease
Avalon clinches majority investment to expand future of diagnostic intelligence
By IPP Bureau - January 20, 2026
The new investment will fuel expansion of Avalon's Diagnostic Intelligence capabilities
Symeres rehires Jurgen Berendsen as CFO amid strategic growth push
By IPP Bureau - January 20, 2026
Berendsen brings over 15 years of financial leadership experience spanning professional services and international trade
IDT and Ansa Biotechnologies join forces to push limits of DNA synthesis
By IPP Bureau - January 20, 2026
The collaboration aims to accelerate the delivery of challenging DNA motifs with speed, precision, and reliability
China nod to two Sanofi drugs for rare and complex conditions
By IPP Bureau - January 20, 2026
Myqorzo, a selective small-molecule cardiac myosin inhibitor, is designed to improve functional capacity and relieve symptoms in oHCM
AbbVie’s Epcoritamab shows progression-free survival gain in relapsed/refractory DLBCL trial
By IPP Bureau - January 20, 2026
Improvements were also seen in complete response rates, duration of response, and time to next treatment
China nod to first homegrown BNCT cancer drug for human trials
By IPP Bureau - January 20, 2026
The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials
AGC Biologics powers commercial launch of its life-changing gene therapy for rare childhood immune disorder
By IPP Bureau - January 20, 2026
Waskyra is an ex vivo gene therapy that uses patients’ own CD34+ hematopoietic stem and progenitor cells, genetically engineered with a lentiviral vector
DNA Nanorobots & AI could slash drug development times, Nanovery CEO says
By IPP Bureau - January 20, 2026
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
Torrent Pharma secures Rs. 12,500 crore for JB Chemicals takeover
By IPP Bureau - January 18, 2026
The capital was raised via multiple-tenure non-convertible debentures (NCDs) and commercial papers
JB Pharma Q3 FY26 PAT up by 22% to Rs. 198 Cr
By IPP Bureau - January 18, 2026
The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26
Bayer welcomes the U.S. Supreme Court decision to review Durnell case in the Roundup litigation
By IPP Bureau - January 17, 2026
Favorable outcome would contribute to significantly containing the Roundup litigation as the company continues its multi-pronged strategy
HDFC Bank to rally 1,500 staff at Tata Mumbai Marathon 2026 to drive cancer awareness
By IPP Bureau - January 17, 2026
The initiative is being led through the Bank’s CSR programme, Parivartan, in partnership with the Indian Cancer Society
EU clears Eylea 8 mg for retinal vein occlusion, expanding use of long-acting eye therapy
By IPP Bureau - January 17, 2026
Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike
